Allogene Therapeutics ALLO

$ 3.0 10.11%

Quarterly report 2024-Q2
added 08-07-2024

Allogene Therapeutics Financial Statements 2011-2024 | ALLO

Annual Financial Statements Allogene Therapeutics

	2023	2022	2021	2020	2019	2018	2017	2016	2015	2014	2013	2012	2011
Market Cap	706 M	912 M	2.03 B	3.04 B	2.24 B	877 M	-	-	-	-	-	-	-
Shares	157 M	143 M	136 M	120 M	101 M	28.9 M	-	-	-	-	-	-	-
Historical Prices	4.5	6.37	14.9	25.2	26	26.9	-	-	-	-	-	-	-
Net Income	-327 M	-340 M	-182 M	-316 M	-185 M	-212 M	-	-	-	-	-	-	-
Revenue	95 K	156 K	114 M	-	-	-	-	-	-	-	-	-	-
Cost of Revenue	-	-	-	-	-	-	-	-	-	-	-	-	-
Gross Profit	-	-	-	-	-	-	-	-	-	-	-	-	-
Operating Income	-328 M	-336 M	-180 M	-258 M	-202 M	-193 M	-	-	-	-	-	-	-
Interest Expense	-17.8 M	-9.44 M	-3.57 M	-67.3 M	-	3.36 M	-	-	-	-	-	-	-
EBITDA	-314 M	-321 M	-170 M	-251 M	-197 M	-191 M	-	-	-	-	-	-	-
Operating Expenses	328 M	336 M	294 M	258 M	202 M	193 M	-	-	-	-	-	-	-
General and Administrative Expenses	71.7 M	79.3 M	74.1 M	65.3 M	57.5 M	41 M	-	-	-	-	-	-	-

All numbers in USD currency

Quarterly Income Statement Allogene Therapeutics

	2024-Q2	2024-Q1	2023-Q4	2023-Q3	2023-Q2	2023-Q1	2022-Q4	2022-Q3	2022-Q2	2022-Q1	2021-Q4	2021-Q3	2021-Q2	2021-Q1	2020-Q4	2020-Q3	2020-Q2	2020-Q1	2019-Q4	2019-Q3	2019-Q2	2019-Q1	2018-Q4	2018-Q3	2018-Q2	2018-Q1	2017-Q4	2017-Q3	2017-Q2	2017-Q1	2016-Q4	2016-Q3	2016-Q2	2016-Q1	2015-Q4	2015-Q3	2015-Q2	2015-Q1	2014-Q4	2014-Q3	2014-Q2	2014-Q1	2013-Q4	2013-Q3	2013-Q2	2013-Q1	2012-Q4	2012-Q3	2012-Q2	2012-Q1	2011-Q4	2011-Q3	2011-Q2	2011-Q1
Shares	190 M	169 M	169 M	168 M	147 M	145 M	144 M	144 M	143 M	141 M	143 M	137 M	135 M	132 M	140 M	127 M	115 M	109 M	124 M	102 M	99.8 M	97.3 M	121 M	4.06 M	3.08 M	26.2 M	26.2 M	26.2 M	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Net Income	-66.4 M	-65 M	-	-61.3 M	-79.2 M	-100 M	-	-83.1 M	-74.8 M	-79.8 M	-	-78.2 M	-70.9 M	-33 M	-	-66.2 M	-61 M	-54.5 M	-61 M	-50.7 M	-41.2 M	-31.6 M	-30.5 M	-43.5 M	-135 M	-2.6 M	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Revenue	-	22 K	-	43 K	22 K	30 K	-	49 K	86 K	61 K	-	49 K	44 K	38.3 M	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Cost of Revenue	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Gross Profit	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Operating Income	-71.4 M	-69.5 M	-	-63 M	-80.5 M	-99.1 M	-	-82.5 M	-76.6 M	-80 M	-	-77.7 M	-71 M	-33.2 M	-	-68 M	-63.2 M	-57.7 M	-64.6 M	-55 M	-46 M	-36.5 M	-33 M	-22.2 M	-135 M	-2.6 M	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Interest Expense	85 K	5.43 M	-	-4.54 M	-2.47 M	2.06 M	-	-1.66 M	1.49 M	492 K	-	-909 K	-531 K	511 K	-	2 M	2.34 M	3.26 M	-	-	4.56 M	4.82 M	-	3.36 M	110 K	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
EBITDA	-	-65.9 M	-	-	-	-95.6 M	-	-71.3 M	-69.2 M	-76.3 M	-	-71.5 M	-67.1 M	-31.3 M	-	-62.4 M	-59.4 M	-55.8 M	-64.6 M	-52.3 M	-44.4 M	-35.9 M	-33 M	-21.5 M	-135 M	-2.6 M	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Operating Expenses	71.4 M	69.5 M	-	63 M	80.6 M	99.1 M	-	82.5 M	76.7 M	80.1 M	-	77.7 M	71.1 M	71.5 M	-	68 M	63.2 M	57.7 M	-	55 M	46 M	36.5 M	-	22.2 M	135 M	2.6 M	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
General and Administrative Expenses	16.1 M	17.3 M	-	17 M	18.5 M	18.9 M	-	18.9 M	19.5 M	19.9 M	-	19 M	18.8 M	16.4 M	-	16.6 M	15.9 M	15.6 M	-	15 M	14.2 M	13.1 M	-	11.3 M	12.5 M	2.6 M	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-

All numbers in USD currency